Our technology OxaSelect is…


Since decades, natural product-based antibiotics are the number one choice for the treatment of patients infected by bacteria. However, rising bacterial resistance limits the clinical application of these promising drugs worldwide. To reinstall their clinical use, AGILeBiotics employs its smart and patented synthetic method OxaSelect that converts existing antibiotics, which lost their efficacy, to novel antibiotic derivatives overcoming bacterial resistance. With this unique technology, AGILeBiotics evades the discovery step and gives promising antibiotics a second life cycle.


Employing natural product-based antibiotics as lead compounds has its limitations as many natural products are structurally complex and require cumbersome syntheses. With our technology OxaSelect we facilitate the modification of existing antibiotics based on natural products. OxaSelect gives facile access to libraries of novel antibiotic candidates based on complex natural products for in vivo and in vitro activity screening. With our patent protected technology and employing existing drugs as lead compounds we aim to shorten the time-to-market period and become a world leader in development of novel antibiotics against life-threatening infections by multidrug resistant bacteria.


The smart synthetic method OxaSelect is solving two problems at the same time. On the one hand, AGILeBiotics can produce quickly a library of novel antibiotic candidates based on structurally complex natural products. On the other hand, OxaSelect allows site-selective modification giving access to modified antibiotics, which overcome clinical relevant bacterial resistance mechanism. Summarized, OxaSelect accelerates drug development, reduces the cost during pre-clinical and clinical trials by up to 40% and 20%, respectively, and gives access to novel antibiotics overcoming bacterial resistance.